Arthur M. Cohen & Associates LLC Grows Position in Axon Enterprise, Inc. (NASDAQ:AXON)

Arthur M. Cohen & Associates LLC boosted its position in shares of Axon Enterprise, Inc. (NASDAQ:AXON - Free Report) by 39.5% during the 1st quarter, according to its most recent 13F filing with the SEC. The fund owned 2,307 shares of the biotechnology company's stock after purchasing an additional 653 shares during the quarter. Arthur M. Cohen & Associates LLC's holdings in Axon Enterprise were worth $1,213,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of AXON. Brighton Jones LLC bought a new stake in shares of Axon Enterprise in the 4th quarter worth $480,000. Caprock Group LLC purchased a new stake in shares of Axon Enterprise during the fourth quarter valued at $329,000. DAVENPORT & Co LLC increased its holdings in Axon Enterprise by 7.6% in the 4th quarter. DAVENPORT & Co LLC now owns 894 shares of the biotechnology company's stock worth $531,000 after buying an additional 63 shares in the last quarter. U.S. Capital Wealth Advisors LLC raised its position in Axon Enterprise by 53.2% in the 4th quarter. U.S. Capital Wealth Advisors LLC now owns 2,032 shares of the biotechnology company's stock worth $1,208,000 after buying an additional 706 shares during the last quarter. Finally, Mather Group LLC. lifted its stake in Axon Enterprise by 3.6% during the 4th quarter. Mather Group LLC. now owns 786 shares of the biotechnology company's stock valued at $467,000 after acquiring an additional 27 shares during the period. 79.08% of the stock is currently owned by institutional investors.

Axon Enterprise Stock Performance

Shares of NASDAQ:AXON traded up $3.49 during midday trading on Friday, hitting $791.85. The company had a trading volume of 443,537 shares, compared to its average volume of 731,575. Axon Enterprise, Inc. has a 12-month low of $278.24 and a 12-month high of $798.16. The company has a fifty day moving average of $638.88 and a two-hundred day moving average of $615.19. The company has a market cap of $61.65 billion, a price-to-earnings ratio of 204.61, a PEG ratio of 5.17 and a beta of 1.24. The company has a debt-to-equity ratio of 0.32, a current ratio of 2.96 and a quick ratio of 2.63.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The biotechnology company reported $1.41 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.34 by $0.07. Axon Enterprise had a return on equity of 7.50% and a net margin of 15.37%. The business had revenue of $603.63 million during the quarter, compared to analyst estimates of $585.67 million. During the same quarter in the previous year, the company posted $1.15 earnings per share. Axon Enterprise's revenue for the quarter was up 31.3% on a year-over-year basis. On average, equities research analysts expect that Axon Enterprise, Inc. will post 5.8 EPS for the current fiscal year.

Insider Buying and Selling

In other news, Director Jeri Williams sold 307 shares of the business's stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $552.72, for a total value of $169,685.04. Following the transaction, the director now directly owns 1,627 shares in the company, valued at $899,275.44. The trade was a 15.87% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Michael Garnreiter sold 5,913 shares of the company's stock in a transaction dated Wednesday, June 4th. The stock was sold at an average price of $760.00, for a total value of $4,493,880.00. Following the completion of the transaction, the director now directly owns 17,740 shares of the company's stock, valued at approximately $13,482,400. This trade represents a 25.00% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 43,969 shares of company stock valued at $29,909,594. 4.40% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of analysts have recently commented on the stock. Needham & Company LLC lifted their price target on shares of Axon Enterprise from $600.00 to $750.00 and gave the stock a "buy" rating in a research note on Thursday, May 8th. The Goldman Sachs Group raised their target price on shares of Axon Enterprise from $730.00 to $830.00 and gave the stock a "buy" rating in a report on Wednesday, May 14th. Craig Hallum lowered shares of Axon Enterprise from a "buy" rating to a "cautious" rating in a research note on Monday, March 10th. Bank of America raised their price target on Axon Enterprise from $750.00 to $895.00 and gave the stock a "buy" rating in a research note on Wednesday. Finally, Northcoast Research cut Axon Enterprise from a "buy" rating to a "neutral" rating in a research report on Wednesday, February 19th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and ten have assigned a buy rating to the company's stock. According to data from MarketBeat, Axon Enterprise has an average rating of "Moderate Buy" and a consensus target price of $699.55.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.